Verteporfin, a suppressor of YAP–TEAD complex, presents promising antitumor properties on ovarian cancer

Yes-associated protein (YAP) is a key transcriptional coactivator of Hippo pathway and has been shown to be an oncoprotein in ovarian cancer (OC). Verteporfin (VP), clinically used in photodynamic therapy for neovascular macular degeneration, has been recently proven to be a suppressor of YAP–TEAD complex and has shown potential in anticancer treatment. In this study, we aimed to explore the potential effect of VP in the treatment of OC. Our results showed that VP led to inhibition of proliferation in a time- and dose-dependent manner and to the suppression of migratory and invasive capacities of OC cells. Western blot and real-time polymerase chain reaction demonstrated that VP induced YAP cytoplasmic retention and deregulated inducible YAP and CCNs in OC cells. In vivo, VP exerted a significant effect on tumor growth in OVCAR8 xenograft mice, resulting in tumor nodules with lower average weight and reduced volume of gross ascites. In addition, VP treatment remarkably upregulated cytoplasmic YAP and phosphorylation YAP and downregulated CCN1 and CCN2, but exerted little effect on YAP-upstream components in Hippo pathway. In conclusion, our results suggested that VP may be a promising agent for OC, acting by suppressing YAP–TEAD complex.

[1]  G. Huet,et al.  Non-Photoinduced Biological Properties of Verteporfin. , 2016, Current medicinal chemistry.

[2]  R. Drapkin,et al.  YAP Induces High-Grade Serous Carcinoma in Fallopian Tube Secretory Epithelial Cells , 2015, Oncogene.

[3]  Jianmin Zhang,et al.  YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage , 2015, Oncogene.

[4]  Valerie M. Weaver,et al.  Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors , 2015, Molecular biology of the cell.

[5]  Jenny J. Li,et al.  A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas , 2015, Front. Oncol..

[6]  Maria Paola Costi,et al.  The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. , 2015, Journal of medicinal chemistry.

[7]  Cheng Wang,et al.  YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression , 2014, Oncogene.

[8]  H. Fan,et al.  YAP/TEAD Co-Activator Regulated Pluripotency and Chemoresistance in Ovarian Cancer Initiated Cells , 2014, PloS one.

[9]  E. Jho,et al.  Cross-talk between Wnt/β-catenin and Hippo signaling pathways: a brief review , 2014, BMB reports.

[10]  J. Ajani,et al.  Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. , 2014, Cancer research.

[11]  J. Olsen,et al.  In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth , 2014, Oncogene.

[12]  J. Kagey,et al.  The role of the Hippo pathway in human disease and tumorigenesis , 2014, Clinical and Translational Medicine.

[13]  F. Ishikawa,et al.  Human cancer growth and therapy in immunodeficient mouse models. , 2014, Cold Spring Harbor protocols.

[14]  Joan W. Miller,et al.  The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. , 2014, Experimental eye research.

[15]  S. Lele,et al.  YAP regulates cell proliferation, migration, and steroidogenesis in adult granulosa cell tumors. , 2014, Endocrine-related cancer.

[16]  H. Fan,et al.  YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients , 2014, PloS one.

[17]  Daniel T. Montoro,et al.  Tumor‐propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis , 2014, The EMBO journal.

[18]  Andrew J Ewald,et al.  A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis , 2014, Genes & development.

[19]  G. Mills,et al.  Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. , 2014, Anticancer research.

[20]  J. Gou,et al.  Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways , 2013, Cancer Chemotherapy and Pharmacology.

[21]  Yuan Cheng,et al.  Actin Cytoskeleton Regulates Hippo Signaling , 2013, PloS one.

[22]  M. Roberge,et al.  The Autophagy Inhibitor Verteporfin Moderately Enhances the Antitumor Activity of Gemcitabine in a Pancreatic Ductal Adenocarcinoma Model , 2013, Journal of Cancer.

[23]  H. Cai,et al.  The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells , 2013, Cell Communication and Signaling.

[24]  B. Karlan,et al.  YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14 , 2012, Oncogene.

[25]  G. Bonamy,et al.  Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. , 2012, Chemistry & biology.

[26]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[27]  Bin Zhao,et al.  The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal , 2011, Nature Cell Biology.

[28]  J. George,et al.  The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene , 2011, Oncogene.

[29]  Xiaolong Yang,et al.  Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. , 2011, Cancer research.

[30]  S. Hilsenbeck,et al.  Hippo pathway effector Yap is an ovarian cancer oncogene. , 2010, Cancer research.

[31]  A. Maitra,et al.  The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. , 2010, Genes & development.

[32]  Ju-Seog Lee,et al.  Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver , 2010, Proceedings of the National Academy of Sciences.

[33]  D. Pearl,et al.  Sphingosine-1-Phosphate Regulates Glioblastoma Cell Invasiveness through the Urokinase Plasminogen Activator System and CCN1/Cyr61 , 2009, Molecular Cancer Research.

[34]  E. Montgomery,et al.  Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.

[35]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[36]  Jianmin Zhang,et al.  Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon , 2006, Proceedings of the National Academy of Sciences.

[37]  Jia-sheng Zheng,et al.  Oncotargets and Therapy , 2022 .